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Abstract: Here we report the enzymologic characterization of recombinant human pitrilysin metallopeptidase 1 (Pitrm1) and derivative mutants including the arginine-to-glutamine substitution
mutant Pitrm1 R183Q, which has been implicated in inherited amyloidogenic neuropathy. Recombinant Pitrm1 R183Q was readily expressed in and purified from Escherichia coli, but was less
active than the recombinant wild-type enzyme against recombinant amyloid beta-peptide (Ab
1-40). A novel fluorogenic substrate derived from the reported Ab 1-40 core peptide cleavage
sequence, Mca-KLVFFAEDK-(Dnp)-OH, was synthesized and applied to real-time kinetic study of
Pitrm1 and derivative mutants including Pitrm1 R183Q. The Pitrm1 R183Q mutant exhibited significantly decreased rate of fluorogenic peptide hydrolysis, yet retained similar binding affinity by
comparison with the wild-type enzyme. Targeted mutagenic analysis revealed a functional
requirement for uncharged or electropositive residues in place of Pitrm1 R183. Residue R183 is
positioned within an N-terminal strand-loop-strand motif that is conserved among M16C, but not
M16A or M16B family metallopeptidases. Truncation analysis revealed that this strand-loopstrand motif inclusive of residue R183 is essential Pitrm1 function. A requirement for charged
residues within 4.5 Å of residue R183 was demonstrated, and Pitrm1 R183Q was found to exhibit
increased sensitivity to heat inactivation. Our findings indicate that charge sharing in the vicinity
of Pitrm1 R183 is critical to enzyme activity, providing potential insight into a molecular basis of
Pitrm1 dysfunction.
Keywords: M16C peptidase; matrix metalloendopeptidase; presequence peptidase; amyloid betapeptide (Ab); neuropathy; amyloidosis

Introduction
Human pitrilysin metallopeptidase 1 (PITRM1: NCBI
gene ID 10531; GENBANK reference sequence
4040225) encodes a 117 kDa metalloendopeptidase of
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the M16C enzyme subfamily.1–3 Also referred to as
matrix metalloendopeptidase (MP1) or mitochondrial
presequence processing peptidase (PreP), the mammalian Pitrm1 gene product, localizes to the mitochondrion, where it plays a role in hydrolysis of
cleaved mitochondrial targeting sequences.4,5 In
mouse models, Pitrm1 is essential to viability, as
homozygous disruption causes embryonic lethality
with complete penetrance.6 Like other enzymes of the
M16 family, Pitrm1 exhibits broad specificity toward
short peptides that is limited in part by the requirement for potential substrates to fit into a central
13,000 cubic Angstrom binding cavity.7,8 Notably,
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Pitrm1 plays a role in the cleavage of amyloid betapeptides (Ab), the accumulation of which has been
associated with amyloid neuropathy.4,5,8–11
A recent study of Norwegian siblings identified
a recessive mutation in the PITRM1 gene
(c548G > A) associated with generalized neurodevelopmental disability, spinocerebellar ataxia, mental
decline, and psychosis.11 The PITRM1 c548G > A
mutation directed incorporation of single amino acid
arginine-to-glutamine substitution at position R183
of the full-length derivative gene product (i.e.,
Pitrm1 R183Q). Pitrm1 R183Q substitution was
associated with amyloidogenic neuropathic phenotype, and impaired mitochondrial function in fibroblasts isolated from siblings bearing the homozygous
missense mutation.11 Fibroblasts from the affected
siblings as well as Pitrm11/– mice exhibited reduced
capacity to degrade Ab peptides, and Pitrm11/– mice
were found to develop progressive ataxia and neurodegenerative phenotype, with accumulation of Ab 1–
42 and mitochondrial targeting signal peptides.11
Brunetti et al. observed that Pitrm1 R183Q
exhibited peptide hydrolytic activity equal to or
greater than that of the wild-type enzyme upon isolation of recombinant human Pitrm1 from Escherichia coli (E. coli).11 However, Pitrm1 R183Q was
unstable when expressed within immortalized
patient fibroblasts, and introduction of the analogous mutation to the budding yeast homolog Cym1p
(i.e., Cym1p R163Q) significantly reduced total cellular levels of the intact mutant protein which were
analyzed by western blot, with evidence of increased
protein degradation for the mutant homolog.11
Accordingly, enzymologic studies of the diseaseassociated Pitrm1 R183Q mutant have remained
limited in nature. The molecular basis of human
Pitrm1 R183Q instability in vivo remains poorly
understood, and direct functional consequences of
R183Q substitution on Pitrm1 activity have not
been reported.
In view of available structural data,6,8,12–14 the
Pitrm1 neuropathic R183Q substitution is positioned
within a conserved N-terminal strand-loop-strand
motif that is restricted to M16C, but not M16A or
M16B family metallopeptidases. This motif is positioned 10 Å distal to the enzyme active site, near
an extended hinge linking N- and C-terminal enzymatic domains. Within and adjacent to the strandloop-strand motif, several charged amino acids are
positioned within 4.5 Å of residue R183. Intriguingly, the functional significance of these residues,
and the enzymatic motif in which they and the
disease-associated substitution are located, has not
been demonstrated.
Here we investigate the molecular basis of
Pitrm1 dysfunction subject to mutation of residue
R183 and its structurally associated residues. We
examine requirements for charge and functional
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group conservation using a novel fluorogenic substrate that may be of broad utility for kinetic study
of enzymes catalyzing Ab peptide hydrolysis. We
observe that loss of peptide hydrolytic function is a
consequence of Pirtm1 R183Q substitution and provide evidence that charge and functional group conservation among residues structurally associated
with Pitrm1 R183 is critical to peptide hydrolysis.

Results
Recombinant expression, purification, and
kinetic characterization of human Pitrm1 and
derivative mutants
Pirtm1 and derivative mutants were expressed in and
isolated from E. coli as C-terminal polyhistidine
tagged fusion partners lacking N-terminal mitochondrial targeting sequence. Peptide hydrolytic activity
was assessed using purified recombinant Ab 1–40,
and internally quenched fluorogenic peptides that
included an established target of Pitrm1 activity (Substrate V), and a novel fluorogenic substrate, McaKLVFFAEDK(Dnp)-OH (Mca: 7-methoxycoumarin-3carboxylic acid; Dnp: 2,4-dinitrophenyl). The McaKLVFFAEDK(Dnp)-OH peptide was developed for use
in this study (peptide synthesis, validation, and standardization are presented in Figs. S1–S3, Supporting
Information). The sequence of this peptide is centered
around the core Pitrm1 cleavage site within Ab 1–40
reported by King et al.8
Pitrm1(A33-R1037)-6xHis (hereafter referred to as
WT) and derivative mutants including the
neuropathy-associated arginine-to-glutamine substitution mutant Pitrm1 R183Q were isolated as soluble proteins of the expected molecular mass [Fig.
1(A)]. As measured using purified recombinant Ab
1–40, Pitrm1 R183Q exhibited substantially attenuated peptide hydrolytic activity relative to WT, yet
retained greater activity than the catalytically inactive E107Q mutant, which served as control [Fig.
1(B, C)]. From densitometric analysis, the specific
activity of R183Q mutant was about half that of the
WT Pitrm1 activity toward Ab 1–40 (3 6 1
nmol min21 mg21 vs. 7 6 1 nmol min21 mg21), while
the E107Q mutation essentially eliminated activity.
To investigate the mechanistic nature of Pitrm1
loss-of-function subject to introduction of the R183Q
substitution, we analyzed kinetic parameters of both
the wild-type enzyme and R183Q substitution
mutant using novel and established fluorogenic substrates [Fig. 2(A–F)]. Pitrm1 R183Q exhibited a fivefold decrease in turnover of Substrate V, and
similarly exhibited a sixfold decrease in turnover of
the fluorogenic Ab-derivative substrate McaKLVFFAEDK(Dnp)-OH [Fig. 2(E,F)]. Thus, by comparison with WT Pitrm1, Pitrm1 R183Q exhibited
significantly decreased activity against multiple peptide substrates.

Pitrm1 Residue R183 Identity is Critical to Peptide Hydrolysis

Figure 1. Recombinant human Pitrm1 R183Q exhibits partial loss of peptide hydrolytic activity towards Ab 1–40 in vitro. (A)
Recombinant human Pitrm1 (WT), a catalytic-site directed mutant lacking peptide hydrolytic activity (E107Q), and the human
amyloid neuropathy associated substitution mutant (R183Q) were expressed in E. coli as C-terminal hexahistidine fusion proteins lacking N-terminal mitochondrial sequences, and purified by nickel affinity chromatography following ultrasonic cell disruption. Approximately 3 lg of each protein was separated by SDS-PAGE and visualized using Coomassie Brilliant BlueTM stain
here and throughout this study. The predicted molecular mass of Pitrm1(A33-R1037)-6xHis is 114.7 kDa. (B) Peptide hydrolysis of
purified recombinant Ab 1–40 by Pitrm1 and derivative mutants, as evaluated by SDS-PAGE. (C) Densitometric analysis of Ab
1–40 peptide hydrolysis by Pitrm1 and derivative mutants, evaluated using BioRad ImageLab 6.0 densitometry software. Mean
values 6 standard error for n 5 2 experimental replicates are shown.

We further evaluated whether reduced peptide
hydrolysis activity observed subject to Pitrm1 R183Q
mutation reflected decreased substrate binding affinity. For assays conducted using Substrate V, there was
no difference in KM between WT Pitrm1 and the
R183Q mutant (4.7 6 0.2 lM and 4.9 6 0.3 lM, respectively). For assays conducted using the Ab-derivative,
the KM for the R183Q mutant was 20% higher than
WT Pitrm1 (7.6 6 0.7 lM and 5.6 6 0.4 lM,
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respectively). Peptide cleavage sites for the internally
quenched fluorogenic Ab-derivative substrate, McaKLVFFAEDK(Dnp)-OH, were comparable to those
reported within the full-length amyloid beta-peptide8
and were similar for both WT and R183Q mutant
(Fig. S4, Supporting Information). Accordingly,
reduced activity of the Pitrm1 R183Q mutant appears
independent of substrate identity and may not be
attributable to defective substrate binding.
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Figure 2. Pitrm1 R183Q exhibits lower rate of fluorogenic peptide hydrolysis, but retains similar peptide binding affinity as compared
to wild-type. Kinetic parameters of peptide hydrolytic function were evaluated for purified recombinant human Pitrm1 derived from the
reference gene sequence (WT Pitrm1) and subject to introduction of the Pitrm1 R183Q substitution associated with amyloid neuropathic disease (R183Q). (A) Reaction progress curves depicting sample fluorescence (RFU) as a function of time (s) for peptide hydrolysis assays conducted using Substrate V, an established target of Pitrm1 activity. (B) Reaction progress curves informing hydrolysis
of Mca-KLVFFAEDK-DNP, a fluorogenic amyloid beta-peptide (Ab) derivative. (C) Specific activity of Pitrm1, Pitrm1 E107Q, and
Pitrm1 R183Q, as determined using Substrate V. Rate of peptide hydrolysis is represented in units of moles product per mole enzyme
per minute, or min21. The mean values 6 standard deviation for n 5 3 experimental replicates are shown here and throughout the
remainder of this study except where stated otherwise. ****P < 0.001 (extremely significant). (D) Specific activity of Pitrm1, Pitrm1
E107Q, and Pitrm1 R183Q, as determined using the Mca-KLVFFAEDK-DNP Ab-derivative peptide. (E) Kinetic parameters for hydrolysis of Substrate V, Mca-RPPGFSAFK(Dnp)-OH. (F) Kinetic parameters for hydrolysis of the Ab derivative peptide McaKLVFFAEDK(Dnp)-OH. Reported KM and Vmax values were determined by nonlinear regression analysis using GraphPad PrismTM.
Error bars that wholly overlap representation of the experimental data have been omitted for clarity.
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Figure 3. Mutational analysis reveals functional requirement
for electropositive or uncharged residues in place of Pitrm1
R183. (A) SDS-PAGE analysis of purified recombinant human
Pitrm1 R183 substitution mutants. Recombinant human
Pitrm1 (WT), a catalytic-site directed mutant lacking peptide
hydrolytic activity (E107Q), and targeted amino acid substitution mutants replacing native Pitrm residue R183 with lysine,
asparagine, alanine, glutamate, or aspartate (R183Q, K, N, A,
E, and D mutants, respectively) were purified from E. coli as
C-terminal hexahistidine fusion proteins lacking N-terminal
mitochondrial sequences. (B) Relative specific activity of
Pitrm1, Pitrm1 E107Q, and Pitrm1 R183-mediated hydrolysis
of Mca-KLVFFAEDK(Dnp)-OH.

Functional conservation of Pitrm1 R183 and
structurally associated residues is critical for
peptide hydrolysis
To inform the structural basis of reduced peptide
hydrolysis activity observed subject to Pitrm1 R183
substitution, we conducted an extended mutagenic
analysis of residue 183 (Fig. 3). Requirements for
conservation of charge, size, and polarity at this
position were evaluated through kinetic analysis of
Pitrm1 R183Q, K, N, A, E, and D substitution
mutants using the Ab-derivative substrate McaKLVFFAEDK(Dnp)-OH [Fig. 3(B)]. All tested substitution mutants of residue 183 were isolated as
highly enriched proteins of the expected molecular
mass [Fig. 3(A)]. The identity of residue 183 was
critical to Pitrm1 activity, as only substitutions that
retained positively charged or uncharged residues in
position 183 were well tolerated. Of the mutants
characterized, only R183K and R183A retained
greater than 20% of WT activity.
Pitrm1 R183 is positioned within a strand-loopstrand motif of the N-terminus that is directly exterior
to the catalytic Zn21 ion, comprising amino acid residues W182-K199 (Fig. 4). This motif links two adjacent alpha helices that are positioned adjacent the
region of defined electron density for Ab 1–40 within
the substrate bound crystal structure and is itself positioned under and adjacent to an extended helical hairpin or hinge (amino acids 510–575), which serves to
connect the N- and C-terminal enzymatic domains.
The strand-loop-strand motif incorporating residue
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R183 is structurally conserved among M16A, but not
M16B or M16C peptidases, and is bounded at either
end by glycine residues positioned about 10 Å from
the catalytic zinc ion. Within this motif, residue R183
is positioned about 14 Å from the catalytic zinc ion
[structural perspectives are presented in Fig. 4(A–C)].
To evaluate the contribution of the strand-loopstrand motif comprising residues W182-K199 in
Pitrm1 activity, we engineered a truncation mutant
bearing full deletion of this region (i.e., Pitrm1
D182–199). The Pitrm1 D182–199 truncation mutant
was isolated as a single molecular weight species of
the expected molecular mass [Fig. 4(D)], yet did not
exhibit detectable peptide hydrolytic activity against
the Ab-derivative substrate Mca-KLVFFAEDK(Dnp)OH [Fig. 4(E)], indicating an essential role for residues of this motif in peptide hydrolysis.

Requirement for charge and functional group
conservation in proximity to Pitrm1 R183
The strand-loop-strand motif comprising residues
W182-K199 and structurally proximate region of the
Pitrm C-terminus contain several conserved charged
residues within potential ionic bonding distance of
Pitrm1 residue R183 [Fig. 5(A)]. For example, residues E185, K199, K901, and E902 are positioned
within 4.5 Å of R183 within the crystal structure of
Pitrm1 in complex with Ab 1–40.8 To assess the role
of these residues in Pitrm1 function, we engineered
charge substitution mutants introducing amino acids
with R-groups bearing charges complementary to
the native enzymatic residues (i.e., E185R, K199E,
K901E, and E902R substitution mutants). Substitution mutants were isolated as highly enriched proteins of the expected molecular mass, and all
mutations had at least some impact on activity [Fig.
5(B,C)]. Intriguingly, the greatest impact on peptide
hydrolytic activity was observed for charge substitutions introduced in place of residues of the strandloop-strand motif. E185R and K199E substitution
mutants retained less than 20% of WT activity, compared with greater than 40% retained activity for
substitutions K901E and E902R, supporting an
important role for charge conservation among residues of the Pitrm1 strand-loop-strand motif adjacent
to residue R183 in enzymatic function.
We next sought to define charge, polarity, and
functional group requirements in Pitrm1 R183adjacent residues E185 and K199, by examining the
role of these residues in enzyme activity (Fig. 6).
E185D, N, Q, A, K and R, and K199R, A, Q, N, D,
and E substitution mutants were constructed, and
their peptide hydrolytic activity was evaluated using
the Ab-derivative substrate Mca-KLVFFAEDK(Dnp)OH. In place of native residue E185, conservation of
electronegative or polar uncharged amino acids containing side-chain carbonyl groups was important
for Pitrm1 function. E185D, N, and Q substitution
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Figure 4. Strand-loop-strand residues W182-K199 are essential for Pitrm1 activity. (A) Structural model of human Pitrm1
(hPreP, RCSB PDB# 4NGE) retaining orientation and coloring conventions of King et al.8 The conserved-strand-loop strand
motif of M16C peptidases comprising residues W182-K199 identified in the current study has been colored deep teal. Pitrm1
N-terminal residues 33–509 are colored purple, and C-terminal residues 576–1037 are colored deep blue. N- and C-terminal
domains are linked by an extended helical hairpin (yellow), which is positioned structurally adjacent to the conserved-strandloop strand motif. Bound Ab (1–40) is represented in gray, while the catalytic zinc ion is colored in green. Enzyme, peptide, and
zinc are presented in cartoon, stick, and sphere format, respectively. (B) Primary sequence alignment of human Pitrm1 and
homologs of the M16C and M16A peptidase subfamilies. HsPitrm1 residue R183 is indicated by an asterisk (*). HsPitrm1 E185
is indicated by a filled arrow (䉲), and of HsPitrm1 K199 is indicated by an open arrow (䉮). HsPitrm1 residues W182-K199 make
up a strand-loop-strand motif restricted to M16C peptidases, indicated by a teal box with solid color outline. (C) Alternative perspective image from PDB# 4NGE showing the position of Pitrm1 residue R183 in structural context (residue R183 is represented in deep teal sticks, with nitrogen atoms colored in blue). (D) SDS-PAGE analysis of purified recombinant human Pitrm,
Pitrm1 E107Q, and a truncation mutant (D182–199) bearing internal deletion of Pitrm1 residues W182-K199. (E) Relative activity
of Mca-KLVFFAEDK(Dnp)-OH peptide hydrolysis by Pitrm1, Pitrm1 E107Q, and Pitrm1D182–199.

mutants retained greater than 45% of WT activity,
compared with less than 20% activity for E185A, K,
and R substitution mutants [Fig. 6(A)]. In place of
native residue K199, conservation of electropositive or
polar uncharged amino acids containing side-chain
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amine groups was important for Pitrm1 function, as
K199R and N substitution mutants retained greater
than 85% of WT activity, compared with less than 20%
activity for K199A, Q, E, and D substitution mutants
[Fig. 6(B)]. Thus, conservation of charge and polarity

Pitrm1 Residue R183 Identity is Critical to Peptide Hydrolysis

additive R183Q substitution in the context of either
the E185 or K199 mutation (i.e., in R183Q/E185R
and R183Q/K199E double mutants) was more detrimental to catalytic activity. In view of these experiments, charge sharing by residues E185R and
K199E appears important for Pitrm1 catalytic activity and may be influenced by residue R183 identity.

Pitrm1 R183Q substitution increases enzyme
thermosensitivity
To investigate whether thermosensitivity of Pitrm1
was increased subject to introduction of R183Q
mutation, we evaluated catalytic activity following
heat treatment at ambient temperatures ranging
from 37 to 578C (Fig. 7). Consistent with the hypothesis that electrostatic interactions formed in proximity to residue R183 are important for Pitrm1
stability, the Pitrm1 R183Q mutant was significantly more sensitive to heat inactivation than the
recombinant WT enzyme. For WT Pitrm1, halfmaximal activity was observed subject to heat treatment at ambient temperature of 498C, significantly
higher than the 428C heat treatment temperature
required for half-inactivation the Pitrm1 R183Q
mutant (Fig. 7).

Discussion
Figure 5. Charge identity of residues proximal to Pitrm1
R183 is important for catalytic function. (A) Putative complementary charge interactions within 4.5 Å of Pitrm1 residue
R183 (yellow dashed lines). Residue numbers and distances
of separation are indicated. An obscuring segment of the
extended helical hairpin (yellow) has been removed for clarity.
Surface lysine methylation was reported to facilitate crystallization but reduce catalytic activity8 and may not reflect the
native state of the enzyme. (B) Specific activity of McaKLVFFAEDK(Dnp)-OH peptide hydrolysis by Pitrm1, Pitrm1
E107Q, R183E, E183R, K199E, K901E, and E902R mutants.
(C) SDS-PAGE analysis of purified recombinant human Pitrm,
Pitrm1 E107Q, and mutants bearing of charge substitutions
in place of Pitrm1 R183 (R183E), or within 4.5 Å of this residue (E185R, K199E, K901E, and E902R).

of residues E185 and K199, which are positioned
within potential ionic binding distance of residue
R183, appears critical for Pitrm1 activity.
To evaluate whether charge sharing between
residues E185 and K199 might contribute to Pitrm1
activity, we introduced reciprocal charge substitution
mutations in these residues alone and subject to
additive R183Q mutation [Fig. 6(C)]. All single-site
and double mutation substitutions targeting residues E185 and K199 were isolated as highly
enriched proteins of the expected molecular mass
[Fig. 6(D–F)]. Intriguingly, reciprocal charge reversal of residues E185 and K199 (i.e., E185R/K199E
double mutation) increased Pitrm1 catalytic activity
relative to that of either mutation alone, while

Smith-Carpenter and Alper

Pitrm1 residue R183 is located within an essential
structural motif that is conserved among enzymes of
the M16C subfamily. The conserved identity of residue R183, and more broadly, conservation of the Nterminal strand-loop-strand motif in which this and
other charged residues are located, is critical to
Pitrm1-mediated peptide hydrolysis. In the context
of this study, Pitrm1 R183Q substitution decreased
Pitrm1 activity in a manner that was independent
of substrate binding affinity or substrate identity
and did not appear to influence major sites of peptide cleavage. Functional requirements for residues
R183, E185, and K199 were demonstrated, indicating that electrostatic interactions formed in proximity to Pitrm1 R183 are critically dependent on
residue identity.
The observed reduction of peptide hydrolytic
activity subject to Pitrm1 R183Q substitution is in
contrast with a prior report (Ref. 11; with expression
and purification further described in Ref. 15). Variability in the reported and observed activity of the
recombinant R183Q mutant may be attributable to
differences in bacterial host genotype, protein
expression construct, cell lysis, and purification
methods, or another conditional difference in the
experimental system that is not resolved here.
At least two potentially significant differences
in experimental design differentiate our work from
that of Brunetti et al.11 First, the expression vector
used by Brunetti et al.11 directed expression of an Nterminally affinity tagged protein bearing deletion of
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Figure 6. Charge sharing by residues E185 and K199 contributes to Pitrm1 activity and may be disrupted subject to R183Q mutation. (A–C) Relative activity of Mca-KLVFFAEDK(Dnp)-OH peptide hydrolysis by Pitrm1, Pitrm1 E107Q, and other targeted substitution mutants, as indicated. (D–F) SDS-PAGE analysis of purified recombinant human Pitrm, Pitrm1 E107Q, and other mutants.

the mitochondrial targeting sequence (i.e., 6xHisPitrm1D1–28), which differs in placement from the
C-terminal polyhistidine tag appended to the
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truncated enzyme (i.e., Pitrm1(A33-R1037)-6xHis) used
in this study. Second, the method of cell lysis (enzymatic digestion with lysozyme vs. mechanical cell

Pitrm1 Residue R183 Identity is Critical to Peptide Hydrolysis

Figure 7. Pitrm1 R183Q substitution increases sensitivity to
thermal inactivation. Relative activity of McaKLVFFAEDK(Dnp)-OH peptide hydrolysis by Pitrm1 and
Pitrm1 R183Q was determined by fluorescence assay at
378C following 3 min pretreatment at the temperatures indicated in the figure legend. Lines of best fit (solid black) and
the limits of their 95% confidence intervals (dashed lines)
were determined through nonlinear regression using the sigmoidal interpolation function of GraphPad PrismTM for n 5 2
experimental replicates. As determined from interpolation of
the line of best fit, 50% inactivation occurred at 49 6 18C for
WT Pitrm1, versus 42 6 18C for the Pitrm1 R183Q mutant
(mean values 6 limits of 95% confidence interval).

disruption by sonication, respectively) differs
between the two studies. Notwithstanding these differences, the WT enzymatic preparation used in this
study retains comparable activity to the enzymatic
preparations of Brunetti et al.,11 and also to that of
Teixeira et al.,15 which is cited as the basis for the
purification method used by Brunetti et al.11
In the current study, available evidence from
size-exclusion chromatography coupled with multiangle laser light scattering analysis (SEC-MALS;
Fig. S5, Supporting Information) indicates the protein preparations are uniform, and that purified
Pitrm1 and derivative mutants are of the expected
molecular size. As determined by SEC, the major
portion of each immobilized metal affinity purified
protein preparation, representing 92–88% by mass
of each purified sample, exhibited mobility between
that of the 156 and 66 kDa MW size standards. For
these products, MALS indicated an absolute molecular mass of 110 kDa, which is consistent with the
predicted mass of monomeric Pitrm1 (114.7 kDa).
We cannot rule out localized defects of protein structure, or even broad conformational defects that are
not immediately evident from this analysis. Yet, the
reported expression and purification method clearly
demonstrates that conservation of Pitrm1 R183 and
surrounding residues is important for enzyme activity and will allow future studies that continue to
explore the importance of the R183Q mutation.
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Intriguingly, the reduction in Pitrm1 R183Q
activity under conditions of this study suggests that
the molecular basis of Pitrm1 R183Q dysfunction
can be studied in vitro using recombinant enzymes
derived from bacterial expression systems, using fluorogenic substrates such as the Ab-derivative peptide developed and reported here. Our observation of
reduced Pitrm1 activity subject to R183Q substitution thus indicates that Pitrm1 R183Q dependent
dysfunction is not solely attributable to disruption of
post-translational modifications that are restricted
to higher eukaryotes. Moreover, as peptide binding
affinities and cleavage sites appear broadly unaffected by introduction of the R183Q substitution, a
direct mechanistic role for Pitrm1 residue R183 in
substrate binding is not supported by our data.
Rather, a model in which charge sharing by residues
near Pitrm1 R183 contributes to enzyme stability or
functional integrity of the enzyme active site is consistent with the increased thermosensitivity of the
Pitrm1 R183Q mutant and requirements for charge
conservation among nearby residues in vitro and is
also consistent with reports of reduced stability of
the Pitrm1 R183Q mutant in higher eukaryotes.11
We therefore conclude that structural and electrostatic properties of the conserved strand-loopstrand motif containing Pitrm1 residue R183, and
indeed the identity of residue R183 itself, are critically important for Pitrm1 function. Mutational disruption of electrostatic interactions in proximity of
Pitrm1 residue R183 contributes to the loss of
enzyme activity observed in this study, and by
extension, may contribute to the loss-of-function
phenotype observed in Pitrm1 R183Q-dependent
neuropathy.

Materials and Methods
Cloning, expression, and purification of human
Pitrm1 and derivative mutants
The human PITRM1 gene used in this study was
obtained from the GE DharmaconTM cDNA library
(GE Health Care Life Sciences, Marlborough, MA;
product #MHS6278–202830697; GENBANK reference sequence 4040225).16,17 To facilitate bacterial
expression of the derivative gene product, PITRM1
was inserted from 50 to 30 at Nde1 and Xho1 cloning
sites, respectively, within the pET-30b(1) expression
vector (Novagen, Hornsby Westfield, NSW, Australia). Plasmid constructs were engineered to direct
expression of a C-terminal hexahistidine fusion protein lacking the N-terminal mitochondrial targeting
sequence of the proenzyme (i.e., Pitrm1(A33-R1037)6xHis).
Derivative mutations in PITRM1 were introduced by circular PCR amplification of the WT
expression construct using mutagenic oligonucleotides (Table S1, Supporting Information), applied in
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R HD cloning kit
conjunction with the In-FusionV
(Takara Bio USA, Ann Arbor, MI). Constructs directing expression of WT Pitrm1 and Pitrm1 R183Q
were validated by DNA sequencing throughout the
full open reading frame, while other clones were validated across the site of mutation or truncation only
(Yale University Keck DNA sequencing facility, New
Haven, CT).
Bacterial cells (strain BL21 DE3, genotype F–
ompT gal dcm lon hsdSB(rB- mB-) k(DE3 [lacI
lacUV5-T7 gene 1 ind1 sam7 nin5]), Novagen)
expressing Pitrm1(A33-R1037)-6xHis or derivative
mutants were cultured in lysogeny broth under antibiotic selection with kanamycin, and induced for
protein expression using 0.1 mM isopropyl b-D-1 thiogalactopyranoside (IPTG). Following induction of
protein expression, cultured cells were grown overnight at 258C, harvested by centrifugation (3200g,
20 min at 48C), rinsed with phosphate buffered
saline, and stored at 2808C prior to cell lysis. On
thawing, cell pellets were lysed by ultrasonic disruption in a lysis/binding/wash buffer containing
300 mM sodium chloride, 50 mM sodium phosphate,
and 10 mM imidazole, pH 7.4, and clarified by centrifugation (3200g for 15 min at 48C). Clarified
lysates were purified by immobilized nickel affinity
chromatography rinsing with 100 column volumes
of binding/wash, and eluting in an equivalent buffer
supplemented to 300 mM imidazole. Protein concentration was determined by Bradford using against
bovine serum albumin (BSA) standards. Proteins
were stored at 2808C in elution buffer supplemented
with 50% glycerol.

Ab 1–40 peptide hydrolysis assays
Amyloid beta-peptide peptide hydrolysis assays were
conducted using purified recombinant Pitrm1 and
derivative mutants (described above), and HFIPtreated purified recombinant Ab 1–40 (rPeptide,
Bogart, GA). The 80 lL assay mixtures contained
0.85 lM Pitrm1 and 50 lM Ab 1–40 in 50 mM potassium phosphate, pH 7.0. Enzyme and substrate premixtures were separately prepared as 23 stocks,
prewarmed to 378C, and then mixed in equal proportion to initiate the peptide hydrolysis assay. Substrate premixtures were sonicated for 5 min at room
temperature prior to warming and initiation of peptide hydrolysis.
Following assembly of the peptide hydrolysis
assay mixture, enzymatic reactions were quenched
at 0, 10, 20, 30, 60, 90, and 120 min intervals by
transfer of 5 lL of the assembled reaction mixture
to 10 lL of SDS-PAGE sample buffer supplemented
with EDTA (400 mM Tris pH 6.8, 25% glycerol, 3%
SDS, 0.005% [w/v] bromophenol blue and 8% bmercaptoethanol, 100 mM EDTA). Quenched samples were held on ice for the duration of the peptide
hydrolysis assay and then treated at 958C for 3 min
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to ensure complete denaturation prior to SDSPAGE. Electrophoretic separation was performed
using Bio-Rad Mini-PROTEAN TGX any kD 15 well
gels, with protein separation performed at 150 V for
40 min in Tris/Glycine SDS buffer system provided
by the manufacturer (Bio-Rad Laboratories; Hercules, CA). Following separation, gels were stained
using colloidal Coomassie Brilliant Blue G250TM in
accordance with the method of Candiano et al.18
Densitometric measurements were obtained using
the Bio-Rad Image Lab software version 6.0. Band
intensity was related to abundance of Ab 1–40 using
a series of internal standards.

Mca-KLVFFAEDK(Dnp)-OH peptide synthesis
and validation
Mca-KLVFFAEDK(Dnp)-OH was synthesized using
standard FMOC/HBTU chemistry with an FMOC
Lys(Dnp) Wang resin on a PS3 peptide synthesizer
(Gyros Protein Technologies, Tucson, AZ). FMOC
deprotection was completed using 20% piperidine.
Each amino acid coupling was performed using
0.4 mmol FMOC protected amino acid, 0.4 mmol
2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate (HBTU), and 0.4M Nmethylmorpholine in dimethylformamide (DMF).
After final FMOC deprotection, the resin was transferred to a 10 mL filtered syringe (Torviq, Tuczon,
AZ) and the N-terminus was derivatized with 7methoxycoumarin-3-carboxylic acid by double coupling with 4 eq. of the coumarin, 4 eq. of HBTU, and
10 eq. of N,N-diisopropylethylamine (DIEA) in DMF.
The first coupling was shaken at room temperature
for 2 h and then the resin was washed with DMF
before the second coupling, which proceeded for
12 h. Resin was then washed with DMF and
dichloromethane (DCM) and dried in a vacuum
desiccator.
The peptide was cleaved from the resin with
10 mL of the cleavage cocktail, containing trifluoroacetic acid (TFA) (90% v/v), thioanisole (5% v/v),
ethanedithiol (3% v/v), and anisole (2% v/v), for 3 h
at room temperature. The peptide was precipitated
by adding the cleavage solution dropwise into cold
diethylether, then centrifuged to a pellet. The peptide pellet was then washed with diethylether and
centrifuged two additional times. The peptide was
purified by reverse-phase HPLC (Shimadzu Prominence, Shimadzu Scientific Instruments, Columbia,
MD) with a Phenomenex Aeris Peptide C-18 semipreparative column (150 3 10 mm; Phenomenex,
Torrence, CA) using a 3 mL/min flow rate and a linear gradient of 40–70% acetonitrile over 15 min. The
peptide was collected, frozen, and lyophilized to yield
a peptide powder. The peptide product mass was
confirmed by MALDI-TOF on a Shimadzu Axima
Confidence mass spectrometer using 2,5-dihydroxybenzoic acid (DHB) as matrix. FMOC Lys(Dnp)
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Wang resin was purchased from Anaspec (Freemont,
CA) and 7-methoxycoumarin-3-carboxylic acid was
purchased from Chemodex (St. Gallen, Switzerland).
The FMOC protected amino acids, HBTU, deprotection solution, activating reagent, TFA, DMF, and
DCM were purchased from Gyros Protein Technologies. All other reagents were purchased from Fisher
Scientific. (Waltham, MA).

FRET assays for Pitrm1 activity
To better assess the impact of Pitrm1 R183Q substitution on peptide hydrolysis activity, novel and
established fluorogenic substrates were employed.
Substrate
V
(7-methoxycoumarin-4-yl-acetylRPPGFSAFK-2,4-dinitrophenyl, R&D Systems, Minneapolis, MN), an established Pitrm1 substrate, was
used much as previously described.4,7 For determination of specific activity, assembled 50 lL assay
mixtures contained 2 nM Pitrm1 and 10 lM initial
concentration of fluorescent substrate in 50 mM
potassium phosphate, pH 7.0. Enzyme and substrate
premixtures were separately prepared and prewarmed to 378C and then mixed to initiate the peptide hydrolysis assay directly prior to analysis. For
studies of Pitrm1 thermosensitivity, enzymatic samples were incubated for 3 min at temperatures ranging from 37 to 578C using the gradient functionality
R PCR thermocycler
of an Eppendorf MastercyclerV
(Eppendorf, Westbury, NY). On initiation of the
enzymatic assay, sample fluorescence was measured
at 378C in 96-well plate format using a BioTek Synergy HT plate reader (excitation: 325 6 25 nm, emission: 420 6 25 nm, BioTek U.S., Winooski, VT).
To examine whether functional consequences of
Pitrm1 R183Q substitution were substratedependent, we synthesized an internally quenched
fluorogenic substrate approximating the primary
Pitrm1 cleavage site in the core amyloidogenic segment of the Ab peptide (i.e., 7-methoxycoumarin-4yl-acetyl-KLVFFAEDK-2,4-dinitrophenyl). The peptide sequence of this substrate reflects the region
inclusive of and directly surrounding Ab 1–40 residue F20, which is positioned directly adjacent the
primary scissile peptide bond in the bound crystal
structure (i.e., in the P1 position8). Ab-derivative
substrate premixtures were sonicated for 5 min at
room temperature prior to warming and input to the
kinetic assay. Quantitative standardization for McaKLVFFAEDK-(Dnp)-OH was based on fluorescence
yield of the hydrolyzed substrate by comparison
with Substrate V. Kinetic parameters were determined by nonlinear regression analysis using the
Michaelis–Menten functionality of GraphPad Prism
7 (GraphPad Software, La Jolla, CA). For all data,
average values from n 5 3 experimental replicates
are depicted 6 standard error of the mean.
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Protein structure and homology modeling
Primary sequence comparisons of Pitrm1 homologs
were generated using default settings of the Clustal
Omega Multiple Sequence Alignment tool (http://
www.ebi.ac.uk/Tools/msa/clustalo/).19–21
NCBI
curated reference sequences were input for alignment as follows: HsPitrm1: NP_001229236.1| presequence protease, mitochondrial isoform 1 precursor
[Homo sapiens], MmPitrm1: NP_660113.1| presequence protease, mitochondrial precursor [Mus musculus], DmCG3107: NP_610156.1| CG3107, isoform
A
[Drosophila
melanogaster],
NP_010718.1|
ScCym1p: [Saccharomyces cerevisiae S288c], AtPreP:
NP_188548.2| presequence protease 1 [Arabidopsis
thaliana], EcPitrilysin: NP_417298.1| protease III
[Escherichia coli str. K-12 substrain MG1655] (characterized in Refs. 1,11,22–26, and elsewhere). All
compared HsPitrm1 homologs except EcPitrilysin
are members of M16C peptidase subfamily. EcPitrilysin is a member of M16A peptidase subfamily frequently referred to by the alternative identifier
Protease III. Aligned sequences were presented
graphically using BOXSHADE (http://www.ch.embnet.org/software/BOX_form.html), supported by the
Swiss Institute of Bioinformatics. Three-dimensional
structural models were based on RCSB PDB#
4NGE8 and were generated using PyMOL (The
PyMOL Molecular Graphics System, Version 1.8,
Schr€odinger, LLC, Cambridge, MA).

Peptide cleavage site mapping of
Mca-KLVFFAEDK(Dnp)-OH
Peptide cleavage sites within the internally quenched
fluorogenic
Ab-derivative
substrate,
McaKLVFFAEDK(Dnp)-OH, were mapped using MALDITOF. Following initiation of the kinetic assay as
described above, 50 lL of a quenching solution containing 170 mM EDTA and 0.07% TFA were added to
the assay mixture after 30 min coincubation with
either WT Pitrm or mutant Pitrm R183Q. Samples
were stored at 2808C until subsequent cleavage site
studies were conducted. For MALDI-TOF mass spectrometry analysis of cleavage sites, 50 lL of the
quenched reaction mixture was removed and the pH
was adjusted to pH 2 with a 0.5 lL aliquot of 10%
TFA. Samples were then prepared with C18 ReversePhase ZipTip (Merck Millipore; Billerica, MA) and
spotted to the MALDI plate with DHB as matrix.
MALDI-TOF mass spectrometry in reflectron mode
and postsource decay MS/MS of major cleavage site
peptide fragments were conducted using the Shimadzu
Axima Confidence mass spectrometer.

Size exclusion chromatography and multi-angle
laser light scattering
SEC-MALS analysis was performed on immobilizedmetal affinity chromatography purified protein
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samples that were otherwise prepared as throughout
this study. The light scattering data were collected
using a Superdex 200, 10/300, HR Size Exclusion
Chromatography (SEC) column (GE Healthcare, Piscataway, NJ), connected to high-performance liquid
chromatography system (HPLC), Agilent 1200 (Agilent Technologies, Wilmington, DE). The elution
from SEC was monitored by a photodiode array
(PDA) UV/VIS detector (Agilent Technologies, Wilmington, DE), differential refractometer (OPTI-Lab
rEx Wyatt, Santa Barbara, CA), static and dynamic,
multiangle laser light scattering (LS) detector
(HELEOS II with QELS capability, Wyatt, Santa
Barbara, CA). The SEC-MALS analysis was performed in PBS buffer. Two software packages were
used for data collection and analysis: the Chemstation software (Agilent Technologies, Wilmington,
DE) controlled the HPLC operation and data collection from the multi-wavelength UV/VIS detector,
while the ASTRA software (Wyatt, Santa Barbara,
CA) collected data from the refractive index detector,
the light scattering detectors, and recorded the UV
trace at 280 nm sent from the PDA detector. The
weight average molecular masses, Mw, were determined across the entire elution profile in the intervals of 1 s from static LS measurement using
ASTRA software as previously described.27
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